Recruiting
Phase 2

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

Sponsor:

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Code:

NCT04945460

Conditions

Hypertension, Pulmonary

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Sotatercept 0.3 mg/kg

Placebo

Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information